The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997

摘要: Introduction Since 1995, the European Association of Pathologists (EAHP) and Society for Hematopathology (SH) have been developing a new World Health Organization (WHO) classification haematological malignancies. The includes lymphoid, myeloid, histiocytic mast cell neoplasms. Design The WHO project involves 10 committees pathologists, who developed lists definitions disease entities. A Clinical Advisory Committee (CAC) international haematologists oncologists was formed to ensure that will be useful clinicians. meeting held in November 1997 discuss clinical issues related classification. Results The has adopted ‘Revised European–American Classification Lymphoid Neoplasms’ (REAL), published 1994 by International Lymphoma Study Group (ILSG), as lymphoid neoplasms. This approach is based on principle list ‘real’ entities, which are defined combination morphology, immunophenotype, genetic features features. relative importance each these varies among diseases, there no one ‘gold standard’. applied principles REAL myeloid neoplasms recognizes distinct entities morphology cytogenetic abnormalities. CAC meeting, organized around series questions, able reach consensus most questions posed. discussed detail below. Among other things, concluded groupings neither necessary nor desirable. Patient treatment determined specific type lymphoma, with addition grade within tumour type, if applicable, prognostic factors such index (IPI). Conclusion The experience produced exciting degree cooperation communication between pathologists from world, should facilitate progress understanding